HGV 0.00% 4.0¢ hygrovest limited

game changer of the industry

  1. 3,462 Posts.
    lightbulb Created with Sketch. 115
    jsut some key points here of this game changer in the industry.
    1) sales scheduled in August 2015, 135,000 per month at a cost of 3 Euros each = 6.66M AU$/per year
    2)2015/Sept 20kg per month of pharmaceutical grade Tetrahydrocannabinol (THC) = 114M AU$/per year
    3) upcoming news: Australia may legalize medical marijuana in August/10th (http://www.rt.com/news/310768-australia-marijuana-medical-legalise/)
    4) recent huge volume indicates a rerate is on the right track.


    http://www.abnnewswire.net/press/en...MMJ_Merger_and_Capital_Raising_Completed.html

    Satipharm, the Company's European Nutraceutical and Pharmaceutical Manufacturer and Wholesale Distributor has commenced production of its GMP-produced CBD food supplement capsules, with first sales scheduled in August 2015, creating an immediate and significant revenue source for the group. The Company is targeting to sell a minimum of 30,000 CBD pills per month, increasing to 135,000 per month at a cost of 3 Euros each.

    Besides the CBD food supplement capsules, Satipharm will be offering pharmaceutical and food grade Cannabis extracts, purified compounds and Active Pharmaceutical Ingredients (APIs) to the industry, through its exclusive agreement with Ai Fame GmbH.
    From September 2015, Satipharm will have up to 20kg per month of pharmaceutical grade Tetrahydrocannabinol (THC), Tetrahydrocannabinolic Acid (THC-A), Cannabidoil (CBD), Cannabidiolic Acid (CBD-A) and Cannabichromene (CBC) and Tetrahydrocannabivarin (THCV) available for sale by February 2016. They are expected to be used for research, product development and processing by other companies.

    This will constitute an industry changing event as these compounds are not currently available in pharmaceutical grade quality. Global research and product developments of Cannabis have also been significantly restricted by the limited supply situation, however Satipharm will have large quantities of APIs available to meet the requirements of large R&D projects. Organically derived APIs from Cannabis are currently traded for up to $350,000 per kg.
 
watchlist Created with Sketch. Add HGV (ASX) to my watchlist
(20min delay)
Last
4.0¢
Change
0.000(0.00%)
Mkt cap ! $8.412M
Open High Low Value Volume
4.1¢ 4.1¢ 4.0¢ $2.407K 60K

Buyers (Bids)

No. Vol. Price($)
3 124832 4.0¢
 

Sellers (Offers)

Price($) Vol. No.
4.4¢ 10000 1
View Market Depth
Last trade - 13.12pm 23/08/2024 (20 minute delay) ?
HGV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.